Health Economics›Colorectal cancer›Advanced or metastatic disease second-line

Advanced or metastatic disease second-line

Colorectal cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Irinotecan and Cetuximab Variant #01	RAS	R 55 838	14d	2.0 mo	5.9 mo	3	R 82 477 PFS proxy	4
FOLFIRI and Panitumumab Variant #01	RAS	R 28 678	14d	6.7 mo	—	2	R 57 355 PFS proxy	1
Irinotecan monotherapy Variant #01	RAS	R 2 716	42d	—	10.9 mo	11	R 29 874 PFS proxy	4
FOLFIRI Variant #05	RAS	R 2 314	14d	5.0 mo	12.1 mo	5	R 11 572 PFS proxy	8

4 of 4 regimens shown